Early tumor-informed circulating tumor DNA (ctDNA) dynamics correlate with response to first-line advanced NSCLC treated with pembrolizumab ± chemotherapy [0.03%]
一线 Pembrolizumab±化疗治疗晚期NSCLC患者的早期肿瘤信息导向循环肿瘤DNA(ctDNA)变化与患者应答相关性研究
Diego Enrico,Gisela Vargas,Gabriela Wulfson et al.
Diego Enrico et al.
Background: Immune checkpoint inhibitors (ICIs), alone or combined with chemotherapy, constitute the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) without actionable oncogenic drivers. Howe...
Circulating tumor cells predict early skeletal-related events in patients with bone metastases from breast cancer [0.03%]
循环肿瘤细胞检测乳腺癌骨转移患者早期发生骨骼相关事件的预测价值
S Grisanti,F Consoli,G Ippolito et al.
S Grisanti et al.
Background: Bone metastases and following skeletal-related events (SREs) are frequent in metastatic breast cancer (MBC) and are a major cause of disability. Circulating tumor cells (CTCs) are prognostic in MBC and are mor...
A serum-clinical composite model for prostate cancer diagnosis: multicenter validation and CRISPR/Cas13a-based detection [0.03%]
前列腺癌诊断的血清-临床综合模型：多中心验证及CRISPR/Cas13a检测方法开发
Cong Lai,Yelisudan Mulati,Xin Huang et al.
Cong Lai et al.
Background: Avoidable prostate biopsies remain a persistent weakness of prostate specific antigen (PSA)- and imaging-led prostate cancer (PCa) diagnosis. The key need is a non-invasive test that improves pre-biopsy risk s...
Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project [0.03%]
基于随机对照临床试验的循环肿瘤DNA（ctDNA）早期变化与预后相关性的研究：来自ctMoniTR项目的新证据
Hillary S Andrews,Nevine Zariffa,Emily M Goren et al.
Hillary S Andrews et al.
Background: Circulating tumor DNA (ctDNA) dynamics have emerged as a promising biomarker of treatment response in oncology drug development. Early decreases in ctDNA levels after treatment initiation are associated with i...
Sex hormone balance and PSA-derived biomarkers in cancer-free African migrant men in Italy: Implications for prostate cancer early detection [0.03%]
意大利无癌非洲移民男性的性激素平衡及PSA衍生生物标志物与前列腺癌早期检测的意义
Felice Crocetto,Matteo Ferro,Gianluigi Carbone et al.
Felice Crocetto et al.
Background: Men of African ancestry experience a disproportionate burden of prostate cancer (PCa), with higher incidence and mortality than men of European ancestry. Although social determinants of health, barriers to car...
ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer [0.03%]
转移性乳腺癌中，ESR1和PIK3CA循环肿瘤DNA（ctDNA）突变状态在变异等位基因分数（VAF）以外的预测生物标志物中的作用
Nicola Fusco,Umberto Malapelle
Nicola Fusco
Circulating tumor DNA (ctDNA) analysis is part of the current clinical practice for the management of hormone receptor (HR)-positive/HER2-negative metastatic breast cancer, particularly for detecting actionable alterations such as ESR1 and ...
A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients [0.03%]
评估三阴性乳腺癌和上皮卵巢癌患者循环肿瘤细胞抗体药物偶联物靶标表达的工作流程
Brian D Henderson,Lauren McMahon,Faye Lewis et al.
Brian D Henderson et al.
Background: Antibody-drug conjugates (ADCs) are transforming the therapeutic landscape of solid tumours. Both patient selection and ADC efficacy in triple-negative breast cancer (TNBC) and epithelial ovarian cancer (EOC) ...
Molecular sampling limits of ctDNA detection in clinical plasma samples [0.03%]
临床血浆样本中ctDNA检测的分子取样局限性
Alexander Gamisch
Alexander Gamisch
Circulating tumor DNA (ctDNA) assays are commonly described by fixed variant allele fraction (VAF)-based limits of detection. However, such metrics overlook a fundamental constraint: the finite number of analyzable DNA molecules in an indiv...
Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors [0.03%]
纵向甲基化ctDNA的增加可预测实体瘤免疫治疗的进展
Muhammad Anees,Patrick L Wagner,Ashten Omstead et al.
Muhammad Anees et al.
Timely identification of treatment failure during immune checkpoint blockade remains a critical unmet need in oncology. We evaluated a tissue-free, methylation-based circulating tumor DNA (ctDNA) assay applied serially across 142 patients w...
Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461] [0.03%]
关于“液态活检在组织分子检测基础上评估转移性非小细胞肺癌患者初始价值的增量”一文的勘误注释
Benjamin A Bleiberg,Dylan G Scholes,Lauren Reed-Guy et al.
Benjamin A Bleiberg et al.
[This corrects the article DOI: 10.1016/j.jlb.2026.100461.]. © 2026 The Author(s).
Published Erratum
The journal of liquid biopsy. 2026 May 7:12:100472. DOI:10.1016/j.jlb.2026.100472 2026